¼¼°èÀÇ ½ÉÀå ÆßÇÁ ½ÃÀå
Heart Pump Devices
»óǰÄÚµå : 1565060
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2024³â 10¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 182 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,233,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,701,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

½ÉÀå ÆßÇÁ ¼¼°è ½ÃÀåÀº 2030³â±îÁö 85¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù

2023³â 27¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ½ÉÀå ÆßÇÁ ¼¼°è ½ÃÀåÀº 2023-2030³âÀÇ ºÐ¼® ±â°£ µ¿¾È ¿¬Æò±Õ 17.6% ¼ºÀåÇÏ¿© 2030³â¿¡´Â 85¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ½É½Ç º¸Á¶ ÀåÄ¡(VADs)´Â CAGR 19.4%¸¦ ±â·ÏÇÏ¿© ºÐ¼® ±â°£ÀÌ ³¡³¯ ¶§±îÁö 51¾ï ´Þ·¯¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ´ëµ¿¸Æ ³» dz¼± ÆßÇÁ(IABPs) ºÎ¹®Àº ºÐ¼® ±â°£ µ¿¾È 14.8%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 7¾ï 2,850¸¸ ´Þ·¯, Áß±¹Àº CAGR 16.6%·Î ¼ºÀå Àü¸Á

¹Ì±¹ ½ÉÀå ÆßÇÁ ½ÃÀåÀº 2023³â 7¾ï 2,850¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö ½ÃÀå ±Ô¸ð°¡ 13¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2023-2030³âÀÇ ºÐ¼® ±â°£ µ¿¾È 16.6%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ´Ù¸¥ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ª ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ µ¿¾È °¢°¢ 15.9%¿Í 14.5%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ ¿¬Æò±Õ 11.4%ÀÇ ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¼¼°è ½ÉÀå ÆßÇÁ ½ÃÀå - ÁÖ¿ä µ¿Çâ ¹× ÃËÁø¿äÀÎ ¿ä¾à

½ÉÀå ÆßÇÁ°¡ ÁøÇ༺ ½ÉºÎÀü Ä¡·á, ½ÉÀå ¼ö¼ú Áö¿ø, ȯÀÚ »ýÁ¸À² Çâ»ó¿¡ ÇʼöÀûÀÎ ÀÌÀ¯´Â ¹«¾ùÀϱî?

½ÉÀå ÆßÇÁ´Â ÁøÇ༺ ½ÉºÎÀü Ä¡·á, ½ÉÀå ¼ö¼ú Áö¿ø, ȯÀÚ »ýÁ¸À² Çâ»ó¿¡ ¾ø¾î¼­´Â ¾È µÉ ÇʼöǰÀÌ µÇ¾ú½À´Ï´Ù. ±×·¸´Ù¸é ¿À´Ã³¯ ÀÌ Àåºñ°¡ ¿Ö ÀÌÅä·Ï Áß¿äÇÑ °ÍÀϱî? Àü ¼¼°èÀûÀ¸·Î ½ÉºÎÀü À¯º´·üÀÌ Áõ°¡ÇÏ´Â °¡¿îµ¥, ÁÂ½É½Ç º¸Á¶ ¼øÈ¯ ÀåÄ¡(LVAD)¿Í Àΰø½ÉÀå(TAH)°ú °°Àº ½ÉÀå ÆßÇÁ´Â ¾à¹° Ä¡·á³ª ±âÁ¸ Ä¡·á¹ý¿¡ ¹ÝÀÀÇÏÁö ¾Ê´Â ȯÀڵ鿡°Ô »ý¸íÀ» ±¸ÇÏ´Â ¼Ö·ç¼ÇÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ½É½Çº¸Á¶ÀåÄ¡(VAD)Àº ±â´É Àå¾Ö°¡ ÀÖ´Â ½ÉÀåÀÌ Ç÷¾×À» º¸´Ù È¿À²ÀûÀ¸·Î ÆßÇÁÁúÇÏ¿© Áß¿äÇÑ Àå±â¿¡ ÃæºÐÇÑ »ê¼Ò¿Í ¿µ¾çÀ» °è¼Ó °ø±ÞÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÜÀ¸·Î½á ½ÉÀå ±â´ÉÀ» º¸Á¶Çϰųª ¿ÏÀüÈ÷ ´ëüÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. ¸¹Àº ¸»±â ½ÉºÎÀü ȯÀڵ鿡°Ô ½ÉÀå ÆßÇÁ´Â ½ÉÀå À̽ÄÀ» ±â´Ù¸®´Â µ¿¾È ¶Ç´Â À̽ÄÀÌ ºÒ°¡´ÉÇÑ °æ¿ì Àå±âÀûÀÎ ´ë¾ÈÀ¸·Î »ý¸íÀ» À¯ÁöÇÒ ¼ö ÀÖ´Â À¯ÀÏÇÑ ´ë¾ÈÀÔ´Ï´Ù.

½ÉºÎÀü °ü¸®»Ó¸¸ ¾Æ´Ï¶ó ½ÉÀå ÆßÇÁ´Â °íÀ§Çè ½ÉÀå ¼ö¼úÀ» ¹Þ´Â ȯÀÚ¸¦ Áö¿øÇÏ´Â µ¥¿¡µµ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ¼ö¼ú¿¡¼­ ½ÉÀå ÆßÇÁ°¡ Á¦°øÇÏ´Â ÀϽÃÀûÀÎ ±â°èÀû ¼øÈ¯ º¸Á¶´Â Ç÷·ù¸¦ À¯ÁöÇÏ°í ¼ö¼ú Áß ¹× ¼ö¼ú ÈÄ ÇÕº´ÁõÀÇ À§ÇèÀ» ÁÙÀÔ´Ï´Ù. ¶ÇÇÑ ½ÉÀ帶ºñ³ª ½ÉÀμº ¼îÅ©¿¡¼­ ȸº¹µÈ ȯÀÚ µî ½ÉÀåÀÌ ½º½º·Î ÃæºÐÇÑ Ç÷¾×À» °ø±ÞÇÒ ¼ö ¾ø´Â ½É°¢ÇÑ »óÅÂÀÇ È¯ÀÚ¸¦ ¾ÈÁ¤½ÃŰ´Â µ¥¿¡µµ Á¡Á¡ ´õ ¸¹ÀÌ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù.

¶ÇÇÑ ½ÉÀå ÆßÇÁ´Â ÇÇ·Î, È£Èí°ï¶õ, ü¾× Àú·ù¿Í °°Àº Áõ»óÀ» ÁÙ¿© ½ÉºÎÀü ȯÀÚÀÇ »îÀÇ ÁúÀ» Å©°Ô Çâ»ó½Ãų ¼ö ÀÖ½À´Ï´Ù. ½ÉÀå ±â´ÉÀ» Áö¿øÇÔÀ¸·Î½á ȯÀÚ´Â ÀÏ»ó »ýȰÀ» ´õ Æí¾ÈÇÏ°Ô ÇÒ ¼ö ÀÖ°í, ½ÅüÀû, Á¤½ÅÀû Çູ°¨À» Çâ»ó½Ãų ¼ö ÀÖ½À´Ï´Ù.

±â¼ú ¹ßÀü°ú Çõ½ÅÀº ¾î¶»°Ô ½ÉÀå ÆßÇÁÀÇ È¿À²¼º, ¾ÈÀü¼º ¹× ¼ö¸íÀ» Çâ»ó½Ã۴°¡?

±â¼úÀÇ ¹ßÀü°ú Çõ½ÅÀº ½ÉÀå ÆßÇÁÀÇ È¿À²¼º, ¾ÈÀü¼º ¹× ¼ö¸íÀ» Å©°Ô Çâ»ó½ÃÄÑ ½ÉºÎÀü ȯÀÚ¿¡°Ô ´õ ¾ÈÁ¤ÀûÀ̰í È¿°úÀûÀÎ ½ÉÀå ÆßÇÁ°¡ µÇ°í ÀÖ½À´Ï´Ù. °¡Àå ¿µÇâ·Â ÀÖ´Â Çõ½Å Áß Çϳª´Â ´õ ÀÛ°í ³»±¸¼ºÀÌ ¶Ù¾î³ª¸ç ´ú ħ½ÀÀûÀÎ ÁÂ½É½Ç º¸Á¶ ¼øÈ¯ ÀåÄ¡(LVAD)ÀÇ °³¹ßÀÔ´Ï´Ù. ÀÌ »õ·Î¿î ¼¼´ëÀÇ LVAD´Â ¼ö¼úÀÇ À§ÇèÀ» ÁÙÀ̰í À̽ÄÇÒ ¼ö ÀÖµµ·Ï ¼³°èµÇ¾î ȯÀÚ¿¡°Ô ´õ ³ªÀº °á°ú¸¦ °¡Á®´Ù ÁÙ ¼ö ÀÖ½À´Ï´Ù. ¼ÒÇüÈ­ ±â¼ú Çõ½ÅÀ¸·Î ÀÎÇØ ÀÌ·¯ÇÑ ÀåÄ¡´Â ÀÌÀü ¸ðµ¨ÀÇ Å©±â ¶§¹®¿¡ ÀÌÀü ¸ðµ¨ÀÇ Å©±â ¶§¹®¿¡ ÀÌÀü¿¡ Èĺ¸ÀÚ°¡ µÉ ¼ö ¾ø¾ú´ø ȯÀÚ¸¦ Æ÷ÇÔÇÏ¿© ´õ ³ÐÀº ¹üÀ§ÀÇ È¯ÀÚ¿¡°Ô ÀûÇÕÇϰԵǾú½À´Ï´Ù. ¶ÇÇÑ, ÀÌ·¯ÇÑ ¼ÒÇüÈ­ µÈ ÀåÄ¡´Â ´ë±Ô¸ð ¼ö¼úÀÇ Çʿ伺À» ÃÖ¼ÒÈ­ÇÏ¿© °¨¿°, Ç÷Àü ¹× ±âŸ ÇÕº´ÁõÀ» À¯¹ßÇÒ °¡´É¼ºÀÌ Àû½À´Ï´Ù.

½ÉÀå ÆßÇÁ ±â¼úÀÇ ¶Ç ´Ù¸¥ Å« ¹ßÀüÀº ¿¡³ÊÁö È¿À²°ú ¹èÅ͸® ¼ö¸íÀÇ °³¼±ÀÔ´Ï´Ù. ÀÌÀü ¼¼´ëÀÇ ½ÉÀå ÆßÇÁ´Â ȯÀÚ°¡ ÈÞ´ëÇØ¾ß ÇÏ´Â ¿ÜºÎ ¹èÅ͸®°¡ ÇÊ¿äÇØ À̵¿¼º°ú ÆíÀǼºÀ» Á¦ÇÑÇß½À´Ï´Ù. ¿À´Ã³¯ ÷´Ü ¹èÅ͸® ±â¼úÀº ´õ ¿À·¡ Áö¼ÓµÇ´Â ÈÞ´ë¿ë Àü¿ø °ø±Þ ÀåÄ¡¸¦ °¡´ÉÇϰÔÇÏ¿© ºó¹øÇÑ ¹èÅ͸® ±³Ã¼ ¹× ÀçÃæÀüÀÇ Çʿ伺À» ÁÙ¿´½À´Ï´Ù. ÀϺΠ±â±â´Â ¹«¼± ÃæÀü ±â¼úÀ» ¿¬±¸Çϰí ÀÖÀ¸¸ç, ÀÌ´Â ¿ÜºÎ Àü¿ø ÄÉÀ̺íÀÌ ÇÊ¿äÇÏÁö ¾Ê¾Æ ȯÀÚÀÇ »îÀÇ ÁúÀ» ´õ¿í Çâ»ó½Ãų ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ °³¼±À¸·Î ½ÉÀå ÆßÇÁ´Â ´õ ½Ç¿ëÀûÀÌ°í ºÎ´ãÀÌ Àû°í, ȯÀÚ´Â ´õ ÀÚÀ¯·Ó°Ô ¿òÁ÷ÀÌ°í ´õ µ¶¸³ÀûÀÎ »îÀ» »ì ¼ö ÀÖ°Ô µË´Ï´Ù.

ÀΰøÁö´É(AI)°ú µ¥ÀÌÅÍ ºÐ¼®ÀÇ ÅëÇÕµµ ½ÉÀå ÆßÇÁÀÇ Áß¿äÇÑ Çõ½ÅÀ¸·Î, AI ±â¹Ý ¸ð´ÏÅ͸µ ½Ã½ºÅÛÀº ±â±âÀÇ ¼º´É°ú ȯÀÚÀÇ »ý¸®Àû ¸Å°³º¯¼ö¸¦ Áö¼ÓÀûÀ¸·Î ÃßÀûÇÏ¿© ÀáÀçÀûÀÎ ¹®Á¦¸¦ Á¶±â¿¡ ¹ß°ßÇÏ°í °íÀåÀ̳ª ¾ÇÈ­ ¡Èĸ¦ ÀÇ·áÁø¿¡°Ô °æ°íÇÒ ¼ö ÀÖ½À´Ï´Ù. ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Áö´ÉÇü ½Ã½ºÅÛÀº ½ÉÀå ÆßÇÁ°¡ ÃÖ»óÀÇ È¿À²·Î ÀÛµ¿Çϵµ·Ï ÀåÄ¡ ¼³Á¤À» ÃÖÀûÈ­ÇÏ°í ½Ç½Ã°£À¸·Î Á¶Á¤ÇÏ´Â µ¥ µµ¿òÀ» ÁÖ¸ç, AI ¾Ë°í¸®ÁòÀº ȯÀÚ°¡ ÀÇ·á °³ÀÔÀÌ ÇÊ¿äÇÑ ½Ã±â¸¦ ¿¹ÃøÇÏ¿© Àå±âÀûÀÎ °á°ú¸¦ °³¼±Çϰí ÇÕº´Áõ À§ÇèÀ» ÁÙÀÏ ¼ö ÀÖ½À´Ï´Ù.

»ýü ÀûÇÕ¼º Àç·á´Â ½ÉÀå ÆßÇÁ°¡ Å©°Ô ¹ßÀüÇϰí ÀÖ´Â ºÐ¾ßÀ̱⵵ ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ÀåÄ¡¿¡ »ç¿ëµÇ´Â ½Å¼ÒÀç´Â ½ÉÀå ÆßÇÁ¿Í °ü·ÃµÈ ÀϹÝÀûÀÎ ÇÕº´ÁõÀÎ Ç÷¾× ÀÀ°í(Ç÷ÀüÁõ)¿Í °¨¿°ÀÇ À§ÇèÀ» ÁÙ¿©ÁÝ´Ï´Ù. ½Åü Á¶Á÷À» ¸ð¹æÇÑ Ã·´Ü ÄÚÆÃ°ú ¼ÒÀ縦 »ç¿ëÇÏ¿© Àåºñ¿¡ ´ëÇÑ ¸é¿ª ü°èÀÇ ¹ÝÀÀÀ» ÃÖ¼ÒÈ­Çϰí Ç÷¾× Èñ¼®Á¦ ¹× ±âŸ ¾à¹°ÀÇ Çʿ伺À» ÁÙÀÔ´Ï´Ù. À̴ ȯÀÚÀÇ ¾ÈÀü¼ºÀ» Çâ»ó½Ãų »Ó¸¸ ¾Æ´Ï¶ó ¸¶¸ð¸¦ ÁÙ¿© ÀåºñÀÇ ¼ö¸íÀ» ¿¬ÀåÇÏ´Â µ¥¿¡µµ µµ¿òÀÌ µË´Ï´Ù.

¿ø°Ý ¸ð´ÏÅ͸µ ±â´ÉÀº ½ÉÀå ÆßÇÁ °ü¸® ¹æ½Ä¿¡µµ º¯È­¸¦ °¡Á®¿À°í ÀÖ½À´Ï´Ù. ½ÉÀå ÆßÇÁ¸¦ Âø¿ëÇÑ È¯ÀÚ´Â Ä¿³ØÆ¼µå Çコ Ç÷§ÆûÀ» ÅëÇØ ¿ø°ÝÀ¸·Î ¸ð´ÏÅ͸µÇÒ ¼ö ÀÖÀ¸¸ç, ÀÇ·á ¼­ºñ½º Á¦°ø¾÷ü´Â ÀåºñÀÇ ¼º´É°ú ȯÀÚÀÇ °Ç°­ ÁöÇ¥¸¦ ½Ç½Ã°£À¸·Î ÃßÀûÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. À̸¦ ÅëÇØ ÀáÀçÀûÀÎ ¹®Á¦¸¦ Á¶±â¿¡ ¹ß°ßÇÒ ¼ö ÀÖ¾î Á÷Á¢ Áø·á¼Ò¸¦ ¹æ¹®ÇÏ´Â ºóµµ¸¦ ÁÙ¿© ȯÀÚ¿Í ÀÇ·áÁø ¸ðµÎ¿¡°Ô ¾Èµµ°¨À» ÁÙ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¿ø°Ý ¸ð´ÏÅ͸µÀÇ ¹ßÀüÀ¸·Î ȯÀÚµéÀº ÀæÀº ÀÔ¿ø ¾øÀ̵µ °³Àκ° ¸ÂÃã Ä¡·á¿Í Ä¡·á °èȹÀ» Á¶Á¤ÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù.

½ÉÀå ÆßÇÁ°¡ ½ÉºÎÀü ȯÀÚÀÇ ÀçÀÔ¿øÀ» ÁÙÀÌ°í ±â´ë ¼ö¸íÀ» ¿¬ÀåÇÏ¸ç »îÀÇ ÁúÀ» ³ôÀÌ´Â µ¥ Áß¿äÇÑ ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

½ÉÀå ÆßÇÁ´Â ½ÉºÎÀü ȯÀÚÀÇ ÀçÀÔ¿øÀ» ÁÙÀ̰í, ¼ö¸íÀ» ¿¬ÀåÇϰí, »îÀÇ ÁúÀ» ³ôÀÌ´Â µ¥ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. ½ÉÀå ÆßÇÁÀÇ °¡Ä¡°¡ ³ôÀº ÁÖµÈ ÀÌÀ¯ Áß Çϳª´Â ¸¸¼º ½ÉºÎÀü ȯÀÚÀÇ ÀçÀÔ¿ø ºóµµ¸¦ ÁÙÀÏ ¼ö Àֱ⠶§¹®ÀÔ´Ï´Ù. ½ÉºÎÀüÀº ½ÉÀåÀÌ Ç÷¾×À» ³»º¸³»´Â ±â´ÉÀÌ ¾àÇØÁ® Áõ»óÀÌ ¹Ýº¹µÇ°í ÀÔ¿øÀ» ¹Ýº¹ÇÏ´Â °ÍÀÌ Æ¯Â¡ÀÔ´Ï´Ù. ½ÉÀå ÆßÇÁ´Â ½ÉÀå ±â´ÉÀ» Áö¼ÓÀûÀ¸·Î Áö¿øÇϰí ȯÀÚÀÇ »óŸ¦ ¾ÈÁ¤È­½ÃÄÑ ÀæÀº ÀÇ·á °³ÀÔÀÇ Çʿ伺À» ÁÙÀÓÀ¸·Î½á À̸¦ ¿ÏÈ­ÇÕ´Ï´Ù. À̴ ȯÀÚÀÇ »îÀÇ ÁúÀ» Çâ»ó½Ãų »Ó¸¸ ¾Æ´Ï¶ó ÀÀ±Þ ÀÇ·á ¹× º´¿ø ÀÚ¿ø¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÁÙ¿© ÀÇ·á ½Ã½ºÅÛ¿¡ ´ëÇÑ ºÎ´ãÀ» ÁÙÀÔ´Ï´Ù.

¼ö¸í ¿¬ÀåÀº ½ÉÀå ÆßÇÁÀÇ ¶Ç ´Ù¸¥ Å« ÀåÁ¡ÀÔ´Ï´Ù. ¸»±â ½ÉºÎÀü ȯÀÚÀÇ ±â´ë ¼ö¸íÀº °í±Þ Ä¡·á¹ýÀÌ ¾ø´Â °æ¿ì ¼ö°³¿ù¿¡¼­ ¼ö³âÀ¸·Î Á¦ÇѵǴ °æ¿ì°¡ ¸¹½À´Ï´Ù. ½ÉÀå ÆßÇÁ, ƯÈ÷ LVAD´Â ȯÀÚ°¡ ½ÉÀå À̽ÄÀ» ±â´Ù¸®´Â µ¿¾È ¶Ç´Â À̽ÄÀÌ ºÒ°¡´ÉÇÑ °æ¿ì Àå±â Ä¡·á·Î ½ÉÀå ±â´ÉÀ» Áö¿øÇÔÀ¸·Î½á »ýÁ¸À²À» Å©°Ô ¿¬Àå½ÃŰ´Â °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. ¸¹Àº °æ¿ì, LVAD¸¦ ÀåÂøÇÑ È¯ÀÚµéÀº ¼ö³â°£ ÀåÄ¡¿Í ÇÔ²² »ýȰÇÒ ¼ö ÀÖ¾î ´Ù¸¥ Ä¡·á¸¦ ¹Þ°Å³ª ´õ ³ªÀº »îÀÇ ÁúÀ» À¯ÁöÇÒ ¼ö ÀÖ´Â ½Ã°£À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÉºÎÀü ȯÀÚÀÇ »îÀÇ ÁúÀ» ³ôÀÌ´Â °ÍÀº ½ÉÀå ÆßÇÁÀÇ Áß¿äÇÑ ÀÌÁ¡ÀÔ´Ï´Ù. ½ÉºÎÀüÀº ȯÀÚÀÇ ÀÏ»ó »ýȰÀ» Å©°Ô Á¦ÇÑÇϰí ÇÇ·Î, ¼û°¡»Ý, ½Åü Ȱµ¿ Âü¿© ´É·Â ÀúÇÏ·Î À̾îÁý´Ï´Ù. ½ÉÀå ÆßÇÁ´Â Ç÷·ù¸¦ °³¼±ÇÏ¿© ÀÌ·¯ÇÑ Áõ»óÀ» ¿ÏÈ­Çϰí ȯÀÚ°¡ ü·Â°ú ¿¡³ÊÁö¸¦ ȸº¹ÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù. ±× °á°ú, ȯÀÚ´Â ´õ Ȱµ¿ÀûÀÎ »îÀ» »ì°í, »çȸ Ȱµ¿¿¡ Âü¿©Çϰí, ´õ Å« µ¶¸³¼ºÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù. ½ÉÀå ÆßÇÁ¸¦ Âø¿ëÇÑ ¸¹Àº ȯÀÚµéÀº ½ÉÀå ÆßÇÁ Âø¿ë ÈÄ ½ÅüÀû, Á¤½ÅÀû Çູ°¨ÀÌ Å©°Ô Çâ»óµÇ¾ú½À´Ï´Ù°í º¸°íÇß½À´Ï´Ù.

½ÉÀå ÆßÇÁ´Â ¶ÇÇÑ ½ÉÀå À̽ÄÀÌ ÀûÇÕÇÏÁö ¾ÊÀº ȯÀÚ¿¡°Ôµµ ´ë¾ÈÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. ³ªÀÌ, ÇÕº´Áõ, ±âÁõÀÚ ½ÉÀåÀÇ À¯¹« µî ¿©·¯ °¡Áö ÀÌÀ¯·Î ½ÉÀå À̽Ŀ¡ ÀûÇÕÇÏÁö ¾ÊÀº ȯÀÚµµ ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ °æ¿ì ½ÉÀå ÆßÇÁ´Â Àå±âÀûÀÎ ÇØ°áÃ¥ÀÌ µÉ ¼ö ÀÖÀ¸¸ç, ½ÉÀå¿¡ ±â°èÀû Áö¿øÀ» Á¦°øÇÏ¿© ȯÀÚ°¡ ´õ ¿À·¡ °Ç°­ÇÏ°Ô »ì ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù. ÀÌ´Â °í·ÉÀÇ È¯ÀÚ³ª À̽ÄÀ» º¹ÀâÇÏ°Ô ¸¸µå´Â ´Ù¸¥ ÁúȯÀ» °¡Áø ȯÀڵ鿡°Ô ƯÈ÷ À¯¿ëÇÕ´Ï´Ù.

½ÉºÎÀü Ä¡·áÀÇ ¿ªÇÒ ¿Ü¿¡µµ ½ÉÀå ÆßÇÁ´Â ½ÉÀμº ¼îÅ© ¹× ½ÉÀå ¸¶ºñ¿Í °°Àº ´Ù¸¥ ½ÉÇ÷°ü Áúȯ°ú °ü·ÃµÈ ÇÕº´ÁõÀ» ¿¹¹æÇÏ´Â µ¥¿¡µµ µµ¿òÀÌ µË´Ï´Ù. ½ÉÀå ÆßÇÁ´Â ÀÌ·¯ÇÑ Áß¿äÇÑ »ç°Ç ¹ß»ý ½Ã ±â°èÀû ¼øÈ¯ Áö¿øÀ» Á¦°øÇÏ¿© ȯÀÚ¸¦ ¾ÈÁ¤½ÃŰ°í ½ÉÀåÀÇ Ãß°¡ ¼Õ»óÀ» ¹æÁöÇϸç Àü¹ÝÀûÀÎ »ýÁ¸À²À» ³ôÀ̰í Àå±âÀûÀÎ ÇÕº´Áõ À§ÇèÀ» ÁÙÀÔ´Ï´Ù.

½ÉÀå ÆßÇÁ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

½ÉºÎÀü À¯º´·ü Áõ°¡, ½ÉÀå ÆßÇÁ ±â¼úÀÇ ¹ßÀü, ¼¼°è Àα¸ÀÇ °í·ÉÈ­, ±â°èÀû ¼øÈ¯ º¸Á¶¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡ µî ¸î °¡Áö Áß¿äÇÑ ¿äÀÎÀÌ ½ÉÀå ÆßÇÁ ½ÃÀåÀÇ ±Þ¼ÓÇÑ ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. ÁÖ¿ä ÃËÁø¿äÀÎ Áß Çϳª´Â Àü ¼¼°è ½ÉºÎÀü À¯º´·ü Áõ°¡ÀÔ´Ï´Ù. Àα¸°¡ °í·ÉÈ­µÇ°í ºñ¸¸, °íÇ÷¾Ð, ´ç´¢º´°ú °°Àº »ýȰ½À°ü ¿äÀÎÀÌ º¸ÆíÈ­µÊ¿¡ µû¶ó ½ÉºÎÀü ȯÀÚ ¼ö´Â ²ÙÁØÈ÷ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ¿¡ µû¶ó ¾à¹° Ä¡·á³ª ´ú ħ½ÀÀûÀÎ Ä¡·á¹ý¿¡ ¹ÝÀÀÇÏÁö ¾Ê´Â ȯÀڵ鿡°Ô È¿°úÀûÀ̰í Àå±âÀûÀÎ ÇØ°áÃ¥À» Á¦°øÇÒ ¼ö ÀÖ´Â ½ÉÀå ÆßÇÁ¿Í °°Àº ÷´Ü Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Å©°Ô Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

½ÉÀå ÆßÇÁ ±â¼úÀÇ ¹ßÀüµµ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎÀÔ´Ï´Ù. ´õ ÀÛ°í ³»±¸¼ºÀÌ ¶Ù¾î³ª¸ç ´ú ħ½ÀÀûÀÎ ÀåÄ¡ÀÇ °³¹ß·Î ÀÎÇØ ½ÉºÎÀü ÁßÁõµµ°¡ ³·°Å³ª ÀÌÀü ¼¼´ëÀÇ ÀåÄ¡¿¡´Â ÀûÇÕÇÏÁö ¾ÊÀº ȯÀÚ µî ´õ ¸¹Àº ȯÀÚ°¡ ½ÉÀå ÆßÇÁ¸¦ »ç¿ëÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú °³¼±Àº ȯÀÚ ¿¹ÈÄ °³¼±, ÇÕº´Áõ °¨¼Ò, »ýÁ¸À² Çâ»óÀ¸·Î À̾îÁ® Àü ¼¼°è ÀÇ·á ½Ã½ºÅÛ¿¡¼­ ½ÉÀå ÆßÇÁÀÇ Ã¤ÅÃÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

¼¼°è Àα¸ÀÇ °í·ÉÈ­µµ ½ÉÀå ÆßÇÁ ½ÃÀåÀÇ ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. Æò±Õ ¼ö¸íÀÌ °è¼Ó ¿¬ÀåµÇ¸é¼­ ½ÉºÎÀüÀ» Æ÷ÇÔÇÑ ³ëÈ­ °ü·Ã ½ÉÇ÷°ü ÁúȯÀÇ ¹ß»ý·üÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. °í·É ȯÀÚ´Â ½ÉÀåÀ» ¾àÈ­½ÃŰ´Â Áúº´¿¡ °É¸± È®·üÀÌ ³ô±â ¶§¹®¿¡ ½ÉÀå ÆßÇÁÀÇ À¯·ÂÇÑ È帱ºÀÌ µÇ°í ÀÖ½À´Ï´Ù. ÇâÈÄ ¼ö½Ê³âµ¿¾È ³ëÀÎ Àα¸°¡ Å©°Ô Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµÊ¿¡ µû¶ó, ³ëÈ­¿¡ µû¸¥ ½ÉºÎÀü Ä¡·á ¿É¼ÇÀ¸·Î ½ÉÀå ÆßÇÁ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

´Ü±â ¹× Àå±â ½Ã³ª¸®¿À¿¡¼­ ±â°èÀû ¼øÈ¯ º¸Á¶¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡µµ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ½ÉÀå ÆßÇÁ´Â °íÀ§Çè ½ÉÀå ¼ö¼ú ÁßÀ̳ª ½ÉÀ帶ºñ ¹× ½ÉÀμº ¼îÅ©¿¡¼­ ȸº¹ ÁßÀΠȯÀÚ µî ÁßȯÀÚ Ä¡·á ÇöÀå¿¡¼­ Á¡Á¡ ´õ ¸¹ÀÌ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ½ÉÀå ÆßÇÁ´Â ȯÀÚ¸¦ ¾ÈÁ¤½Ã۰í ȸº¹À» µ½´Â ´É·ÂÀ¸·Î ÀÎÇØ ½ÉÀå Àü¹®ÀÇ¿Í ½ÉÀå ¿Ü°ú Àǻ翡°Ô ±ÍÁßÇÑ µµ±¸°¡ µÇ°í ÀÖÀ¸¸ç, º´¿ø°ú ÀÇ·á ½Ã¼³¿¡¼­ÀÇ Ã¤ÅÃÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

¶ÇÇÑ, ¸¸¼º ½ÉÀåÁúȯ ȯÀÚÀÇ »îÀÇ Áú(QOL) Çâ»ó¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ ½ÃÀå ¼ºÀå¿¡ ÈûÀ» º¸Å°í ÀÖ½À´Ï´Ù. ȯÀÚ¿Í ÀÇ·áÁøÀÌ »ý¸í ¿¬ÀåÀº ¹°·Ð ÀÏ»óÀûÀÎ ±â´ÉÀ» Çâ»ó½Ãų ¼ö ÀÖ´Â ¼Ö·ç¼ÇÀ» ã°í ÀÖ´Â °¡¿îµ¥, ½ÉÀå ÆßÇÁ´Â ½ÉºÎÀü °ü¸®¿¡ ÇʼöÀûÀÎ ¿É¼ÇÀ¸·Î ¿©°ÜÁö°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÀåÄ¡°¡ Á¦°øÇϴ ȯÀÚÀÇ À̵¿¼º Çâ»ó, Áõ»ó ¿ÏÈ­, Àü¹ÝÀûÀÎ »îÀÇ Áú °³¼±Àº »ç¿ë Áõ°¡ÀÇ ÁÖ¿ä µ¿±â°¡ µÇ°í ÀÖ½À´Ï´Ù.

¶ÇÇÑ, Á¤ºÎÀÇ Áö¿ø°ú ½ÉÀå ÆßÇÁ¿¡ ´ëÇÑ ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎÀ¸·Î ÀÌ·¯ÇÑ »ý¸íÀ» ±¸ÇÏ´Â ±â¼ú¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ¹Ì±¹ ½ÄǰÀǾ౹(FDA)°ú À¯·´ÀǾàǰû(EMA)°ú °°Àº ±ÔÁ¦ ±â°üÀº »õ·Î¿î ½ÉÀå ÆßÇÁ¿Í Çõ½Å ±â¼úÀ» ½ÂÀÎÇϰí ÀÖÀ¸¸ç, ÀÇ·áÁø°ú ȯÀÚµéÀÌ ÀÌ·¯ÇÑ ±â¼úÀ» º¸´Ù ±¤¹üÀ§ÇÏ°Ô ÀÌ¿ëÇÒ ¼ö ÀÖµµ·Ï Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±ÔÁ¦ ´ç±¹ÀÇ Áö¿øÀº ½ÃÀå È®´ë¿Í Â÷¼¼´ë ½ÉÀå ÆßÇÁ ±â¼ú °³¹ßÀ» ÃËÁøÇÏ´Â µ¥ ÀÖ¾î ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù.

°á·ÐÀûÀ¸·Î, ½ÉÀå ÆßÇÁ ½ÃÀåÀÇ ¼ºÀåÀº ½ÉºÎÀü À¯º´·ü Áõ°¡, ±â¼ú ¹ßÀü, ¼¼°è Àα¸ÀÇ °í·ÉÈ­, ±â°èÀû ¼øÈ¯ º¸Á¶¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î ÀÎÇØ ¹ß»ýÇÕ´Ï´Ù. ½ÉÀå ÆßÇÁ´Â °í±Þ ½ÉÀ庴 °ü¸®¸¦ À§ÇÑ Áß¿äÇÑ ¼Ö·ç¼ÇÀ¸·Î ÀÇ·á ½Ã½ºÅÛ¿¡¼­ °è¼Ó äÅõǰí ÀÖÀ¸¸ç, ½ÉÀå ÆßÇÁ´Â ȯÀÚÀÇ »ýÁ¸À²À» ³ôÀÌ°í º´¿ø ÀçÀÔ¿øÀ» ÁÙÀ̸ç Àü ¼¼°è ½ÉºÎÀü ȯÀÚÀÇ »îÀÇ ÁúÀ» Çâ»ó½ÃŰ´Â µ¥ Á¡Á¡ ´õ Áß¿äÇÑ ¿ªÇÒÀ» ÇÒ °ÍÀÔ´Ï´Ù.

Á¶»ç ´ë»ó ±â¾÷ ¿¹½Ã(ÃÑ 13°³»ç)

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Heart Pump Devices Market to Reach US$8.5 Billion by 2030

The global market for Heart Pump Devices estimated at US$2.7 Billion in the year 2023, is expected to reach US$8.5 Billion by 2030, growing at a CAGR of 17.6% over the analysis period 2023-2030. Ventricular Assist Devices (VADs), one of the segments analyzed in the report, is expected to record a 19.4% CAGR and reach US$5.1 Billion by the end of the analysis period. Growth in the Intra-aortic Balloon Pumps (IABPs) segment is estimated at 14.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$728.5 Million While China is Forecast to Grow at 16.6% CAGR

The Heart Pump Devices market in the U.S. is estimated at US$728.5 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.3 Billion by the year 2030 trailing a CAGR of 16.6% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 15.9% and 14.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 11.4% CAGR.

Global Heart Pump Devices Market - Key Trends and Drivers Summarized

Why Are Heart Pump Devices Becoming Essential for Treating Advanced Heart Failure, Supporting Cardiac Surgeries, and Improving Patient Survival Rates?

Heart pump devices have become essential for treating advanced heart failure, supporting cardiac surgeries, and improving patient survival rates. But why are these devices so critical today? With the rising prevalence of heart failure globally, heart pump devices, such as left ventricular assist devices (LVADs) and total artificial hearts (TAHs), are providing life-saving solutions for patients who are no longer responsive to medication or traditional therapies. These devices are crucial in assisting or completely replacing the function of a failing heart by helping it pump blood more effectively, ensuring that vital organs continue to receive sufficient oxygen and nutrients. For many patients with end-stage heart failure, heart pump devices are the only viable option to sustain life while waiting for a heart transplant or as a long-term alternative when transplants are not an option.

In addition to managing heart failure, heart pump devices play a vital role in supporting patients undergoing high-risk cardiac surgeries. In such procedures, temporary mechanical circulatory support provided by heart pump devices ensures that blood flow is maintained, reducing the risk of complications during and after surgery. These devices are also being increasingly used to stabilize patients in critical conditions, such as those recovering from heart attacks or cardiogenic shock, where the heart cannot pump enough blood on its own.

Moreover, heart pump devices significantly improve the quality of life for heart failure patients by reducing symptoms like fatigue, shortness of breath, and fluid retention. By supporting the heart’s function, these devices allow patients to engage in everyday activities with greater ease, improving both physical and mental well-being.

How Are Technological Advancements and Innovations Enhancing the Efficiency, Safety, and Longevity of Heart Pump Devices?

Technological advancements and innovations are significantly enhancing the efficiency, safety, and longevity of heart pump devices, making them more reliable and effective for patients with heart failure. One of the most impactful innovations is the development of smaller, more durable, and less invasive left ventricular assist devices (LVADs). These newer-generation LVADs are designed to be implanted with fewer surgical risks and provide better outcomes for patients. Innovations in miniaturization have allowed these devices to fit into a broader range of patients, including those who previously might not have been candidates due to the size of earlier models. These smaller devices also cause fewer complications, such as infections or blood clots, by minimizing the need for extensive surgical procedures.

Another significant advancement in heart pump technology is the improvement of energy efficiency and battery life. Earlier generations of heart pump devices required external batteries that patients had to carry with them, limiting mobility and convenience. Today, advanced battery technologies allow for longer-lasting, portable power supplies, reducing the need for frequent battery changes or recharging. Some devices are even exploring wireless charging technologies, which would eliminate the need for external power cables and further enhance the patient’s quality of life. These improvements make heart pump devices more practical and less burdensome, allowing patients to move more freely and live more independently.

The integration of artificial intelligence (AI) and data analytics is another key innovation in heart pump devices. AI-powered monitoring systems can continuously track the device's performance and the patient’s physiological parameters, detecting potential issues early and alerting healthcare providers to any signs of malfunction or deterioration. These intelligent systems help optimize device settings and make real-time adjustments to ensure the heart pump is working at peak efficiency. AI algorithms can also predict when a patient may need medical intervention, improving long-term outcomes and reducing the risk of complications.

Biocompatible materials are another area where heart pump devices are seeing significant improvements. New materials used in these devices reduce the risk of blood clotting (thrombosis) and infection, which are common complications associated with heart pumps. The use of advanced coatings and materials that mimic the body’s tissues minimizes the immune system’s response to the device, reducing the need for blood thinners and other medications. This not only enhances patient safety but also extends the longevity of the device by reducing wear and tear.

Remote monitoring capabilities are also transforming the way heart pump devices are managed. Patients with heart pumps can now be monitored remotely through connected health platforms, where healthcare providers can track device performance and patient health metrics in real-time. This allows for early detection of potential issues, reduces the frequency of in-person clinic visits, and provides peace of mind to both patients and clinicians. In addition, advancements in remote monitoring are making it easier for patients to receive personalized care and adjustments to their treatment plans without the need for frequent hospital stays.

Why Are Heart Pump Devices Critical for Reducing Hospital Readmissions, Extending Life Expectancy, and Enhancing Quality of Life for Heart Failure Patients?

Heart pump devices are critical for reducing hospital readmissions, extending life expectancy, and enhancing the quality of life for heart failure patients because they provide a long-term solution for those with severe heart conditions. One of the primary reasons heart pump devices are so valuable is their ability to reduce the frequency of hospital readmissions in patients with chronic heart failure. Heart failure is often characterized by recurring symptoms, leading to repeated hospitalizations as the heart becomes less effective at pumping blood. Heart pump devices alleviate this by consistently supporting the heart’s function, stabilizing the patient’s condition, and reducing the need for frequent medical interventions. This not only improves the patient’s quality of life but also reduces the strain on healthcare systems by lowering the demand for emergency care and hospital resources.

Extending life expectancy is another significant benefit of heart pump devices. For patients with end-stage heart failure, life expectancy is often limited to a few months or years without advanced treatment options. Heart pump devices, particularly LVADs, have been shown to significantly extend survival rates by supporting heart function while patients wait for a heart transplant or as a long-term therapy when transplantation is not feasible. In many cases, patients with LVADs can live for several years with the device, providing them with more time to receive other treatments or maintain a better quality of life.

Enhancing the quality of life for heart failure patients is a key advantage of heart pump devices. Heart failure can severely limit a patient’s ability to perform daily activities, leading to fatigue, shortness of breath, and a reduced ability to participate in physical activities. Heart pump devices help alleviate these symptoms by improving blood flow, allowing patients to regain their strength and energy. This, in turn, enables them to lead more active lives, participate in social activities, and experience a greater sense of independence. Many patients with heart pump devices report significant improvements in their physical and emotional well-being after receiving the device.

Heart pump devices also offer an alternative for patients who are not eligible for heart transplants. For various reasons, including age, comorbidities, or the availability of donor hearts, some patients may not be suitable candidates for heart transplantation. In these cases, heart pump devices serve as a long-term solution, providing mechanical support to the heart and allowing patients to live longer, healthier lives. This is particularly valuable for older patients or those with other medical conditions that complicate their candidacy for a transplant.

In addition to their role in treating heart failure, heart pump devices also help prevent complications related to other cardiovascular conditions, such as cardiogenic shock or heart attacks. By providing mechanical circulatory support during these critical events, heart pump devices can stabilize patients and prevent further damage to the heart, improving overall survival rates and reducing the risk of long-term complications.

What Factors Are Driving the Growth of the Heart Pump Devices Market?

Several key factors are driving the rapid growth of the heart pump devices market, including the increasing prevalence of heart failure, advancements in heart pump technology, the aging global population, and the rising demand for mechanical circulatory support. One of the primary drivers is the growing prevalence of heart failure worldwide. As populations age and lifestyle factors such as obesity, hypertension, and diabetes become more common, the number of individuals suffering from heart failure is steadily increasing. This has created a significant demand for advanced treatment options, such as heart pump devices, that can provide effective, long-term solutions for patients who are no longer responsive to medication or less invasive therapies.

Advancements in heart pump technology are another major factor fueling the growth of the market. The development of smaller, more durable, and less invasive devices has made heart pumps more accessible to a broader range of patients, including those with less severe heart failure or those who may not have been candidates for older-generation devices. These technological improvements have also led to better patient outcomes, fewer complications, and increased survival rates, driving the adoption of heart pump devices in healthcare systems around the world.

The aging global population is also contributing to the growth of the heart pump devices market. As life expectancy continues to rise, the incidence of age-related cardiovascular conditions, including heart failure, is increasing. Older patients are more likely to suffer from conditions that weaken the heart, making them prime candidates for heart pump devices. With the number of elderly individuals projected to grow significantly over the coming decades, the demand for heart pumps as a treatment option for age-related heart failure is expected to rise.

The rising demand for mechanical circulatory support in both short-term and long-term scenarios is another factor driving market growth. Heart pump devices are increasingly being used in critical care settings, such as during high-risk cardiac surgeries or for patients recovering from heart attacks or cardiogenic shock. The ability of heart pump devices to stabilize patients and support recovery has made them a valuable tool for cardiologists and cardiac surgeons, further driving their adoption in hospitals and healthcare facilities.

The growing focus on improving the quality of life for patients with chronic heart conditions is also propelling the market. As patients and healthcare providers seek solutions that not only extend life but also enhance day-to-day functioning, heart pump devices are being viewed as an essential option for managing heart failure. The improvements in patient mobility, reduction in symptoms, and overall better quality of life provided by these devices are significant motivators for their increasing use.

Additionally, government support and regulatory approvals for heart pump devices are expanding access to these life-saving technologies. Regulatory bodies, such as the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA), are increasingly approving new heart pump devices and innovations, making these technologies more widely available to healthcare providers and patients. This regulatory support is crucial for driving market expansion and fostering the development of next-generation heart pump technologies.

In conclusion, the growth of the heart pump devices market is driven by the rising prevalence of heart failure, advancements in technology, the aging global population, and the increasing demand for mechanical circulatory support. As healthcare systems continue to adopt heart pump devices as a critical solution for managing advanced heart conditions, these devices will play an increasingly vital role in improving patient survival, reducing hospital readmissions, and enhancing the quality of life for heart failure patients worldwide.

Select Competitors (Total 13 Featured) -

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â